Blockade of the immune checkpoints programmed death-1 (PD-1) and cytotoxic lymphocyte antigen 4 has improved outcomes for patients with hepatocellular carcinoma (HCC), yet most still fail to achieve objective clinical benefit. MET plays key roles in both HCC tumorigenesis and immunosuppressive conditioning; however, inhibition of MET causes upregulation of PD-ligand 1 (PD-L1) suggesting the use of these inhibitors in the context of PD-1 blockade. We sought to investigate across the Hepa1-6, HCA-1 and diethylnitrosamine (DEN) models of HCC whether the combination of more specific type I versus more pleiotropic type II MET inhibitors would confer superior outcomes in combination with PD-1 blockade.
View Article and Find Full Text PDFA straightforward and stepwise functionalization of poly(limonene carbonate) (PLC) was achieved through the use of thiol-ene click chemistry introducing primary amine groups. These amines are initiating points for -carboxy anhydride (NCA) ring-opening polymerization (ROP) reactions, allowing us to modify the PLC backbone with oligolysine fragments, thereby creating a polymer brush type macromolecule. These newly prepared biohybrid structures show a clear hydrophilic behavior as evident from their physical behavior and contact angle measurements.
View Article and Find Full Text PDFPharmaceuticals (Basel)
April 2024
An inflammation-resolving polysialic acid-decorated PLGA nanoparticle (PolySia-NP) has been developed to treat geographic atrophy/age-related macular degeneration and other conditions caused by macrophage and complement over-activation. While PolySia-NPs have demonstrated pre-clinical efficacy, this study evaluated its systemic and intraocular safety. PolySia-NPs were evaluated in vitro for mutagenic activity using strains and , with and without metabolic activation; cytotoxicity was evaluated based on its interference with normal mitosis.
View Article and Find Full Text PDF